Vaccine for bladder cancer after standard treatment fails
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an investigational vaccine for people with a type of bladder cancer that has come back after receiving standard treatments (BCG or chemotherapy into the bladder). The vaccine is designed to help the immune system fight the cancer. It may be an option if your cancer is limited to the lining of the bladder and you are otherwise in good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with non-muscle invasive bladder cancer (cancer only in the lining of the bladder) that has come back after at least one course of BCG or chemotherapy given directly into the bladder within the last 2 years.
- You have had complete removal of the visible tumor by a procedure called TURBT, and you have no signs of cancer at the time of screening (though some flat, non-invasive spots called CIS may be allowed).
- You are able to start treatment within 8 weeks after your last TURBT procedure.
- You are generally in good physical condition (able to care for yourself).
- Women who can get pregnant must use effective birth control and have negative pregnancy tests; men must use a condom for 1 week after each treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental mRNA vaccine (V940) combined with BCG therapy for people with high-risk non-muscle invasive bladder cancer that hasn't spread. It aims to see if the vaccine can help the immune system better fight the cancer.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
This trial tests whether a specific schedule of BCG (a weakened germ that boosts the immune system) placed directly into the bladder is safe and effective for medium- to high-risk bladder cancer that hasn't grown into the muscle. It aims to see if adjusting the standard BCG course can work better for people with a PD-L1-positive tumor.
This study tests an investigational virus injection given directly into the bladder to treat high-risk bladder cancer that hasn't spread into the muscle. The goal is to see if it's safe and effective in preventing cancer from coming back or getting worse.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a combination of an immunotherapy drug (toripalimab) and a chemotherapy drug (gemcitabine) given directly into the bladder after surgery to remove high-risk bladder tumors. The goal is to reduce the chance of the cancer coming back.
Hear when a new Urinary Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.